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HIV atrophy induces modification of 
subcutaneous adipose tissue architecture: 
in vivo visualization by high-resolution 
magnetic resonance imaging
The utility of high-resolution magnetic resonance imag-
ing (MRI) of HIV-induced atrophy was compared with that 
of dual energy X-ray absorptiometry (DEXA). The calf and 
lumbar regions were studied in three groups of patients: 
HIV patients with lipoatrophy, HIV patients without lipoat-
rophy and healthy volunteers. High-resolution MRI enabled 
identification of a clear disorganization of adipose tissue in 
patients with lipoatrophy. In addition, these patients pre-
sented a very small adipose thickness on the calf and a 
very small nodule size. Results led to the hypothesis that 
adipose tissue disorganization appears before changes in 
DEXA measurements or clinically visible modifications. 
Br J Dermatol 160: 741–6.
Troglitazone suppresses TGF-β1-induced 
collagen type I expression in keloid fibroblasts
Zhang et al. investigated the effect of the peroxisome pro-
liferator-activated receptor (PPAR)-γ agonist troglitazone 
on transforming growth factor (TGF)-β1-induced collagen 
type I expression in keloid fibroblasts. These were cultured 
and exposed to different concentrations of troglitazone in 
the presence of TGF-β1. PPAR-γ was expressed at a mod-
erate level in keloid fibroblasts. Troglitazone depressed 
TGF-β1-stimulated collagen type I expression and collagen 
synthesis in keloid fibroblasts in a concentration-dependent 
manner. Moreover, troglitazone inhibited expression and 
phosphorylation of TGF-β1-induced Smad2/3. Cell viabil-
ity was unaffected. These inhibitory effects of troglitazone 
were reversed by the PPAR-γ-specific antagonist GW9662. 
These results suggest that PPAR-γ is present in keloid fibro-
blasts and that PPAR-γ activation inhibits TGF-β1-induced 
collagen type I expression at least in part by decreasing 
collagen synthesis. PPAR-γ may be a promising therapeutic 
target for keloids. Br J Dermatol 160: 762–70.
Shrinkage of skin excision specimens: 
formalin fixation is not the culprit
The objective of this study was to determine the magnitude 
of changes in size and the factors influencing the retrac-
tion of skin excision specimens. Three measurements of 82 
skin excision specimens—consisting of length and width 
of the planned surgical excision (in vivo), length, width 
and depth of the specimens following excision (ex vivo) 
and of the specimens after formalin fixation (in vitro)—
were performed and compared using a nonparametric 
paired test. Shrinkage of skin excision specimens occurred 
immediately after surgical excision and prior to formalin 
fixation. Patients’ age, sex and type of skin lesion did not 
influence the amount of shrinkage. Length shrinkage was 
more important for specimens excised from the extrem-
ities and increased with initial length and smaller width. 
Br J Dermatol 160: 820–4.
Nickel allergy as risk factor for hand eczema: 
a population-based study
The relation between nickel allergy and hand eczema 
was studied. Three hundred and sixty-nine women were 
patch tested and clinically investigated regarding hand 
eczema. Patch tests showed 30.1% nickel-positive indi-
viduals. When analysing all participants, there was no 
statistically significant difference between nickel-positive 
and nickel-negative women regarding occurrence of hand 
eczema. The most important risk factor for hand eczema 
was childhood eczema. The risk for hand eczema in nickel-
positive women may previously have been overestimated. 
Br J Dermatol 160: 838–44.
Efficacy and safety of tacrolimus ointment 
0.1% vs. betamethasone 17-valerate 0.1%  
in the treatment of chronic paronychia:  
an unblinded randomized study
The objective of this randomized, unblinded, comparative 
study was to compare the efficacy of tacrolimus ointment 
0.1% vs. betamethasone 17-valerate 0.1% in the treatment of 
chronic paronychia. Forty-five patients with chronic parony-
chia were randomized to apply twice daily either betame-
thasone 17-valerate 0.1% or tacrolimus 0.1% ointment 
or emollient. Protective measures were counselled to all 
patients. Treatment duration was 3 weeks and patients were 
followed for an additional 6 weeks. Both betamethasone and 
tacrolimus groups presented statistically significant cure or 
improvement rates when compared with the emollient group 
(P < 0.001). In addition, tacrolimus ointment appeared to 
be more efficacious than betamethasone 17-valerate for the 
treatment of chronic paronychia. Br J Dermatol 160: 874–6.
